Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of ~~pharmaceutical composition for~~ preventing~~,~~ or treating~~, or prophylaxis of~~ arthrosis in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) a substance that modulates ~~having an activity in modulating~~ signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier.

2. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, wherein the substance inhibits ~~has an activity in inhibiting~~ proliferation of AILIM-expressing cells or inhibits ~~in inhibiting~~ production of a cytokine by AILIM-expressing cells.

3. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 2 ~~1~~, wherein the cytokine is interferon γ ~~which is a cytokine produced by Th1 type T cells,~~ or interleukin 4 ~~which is a cytokine produced by Th2 type T cells~~.

4. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, wherein the arthrosis is rheumatoid arthritis.

5. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, wherein the arthrosis is osteoarthritis.

6. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, wherein the substance is a protein ~~substance~~.

7. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 6, wherein the protein ~~substance~~ is selected from the group consisting of:

a) an antibody that ~~which~~ binds to AILIM or a portion thereof;

b) a polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM;

c) a fusion polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM and all ~~the whole~~ or a portion of a constant region of an immunoglobulin heavy chain; and

d) a polypeptide that ~~which~~ binds to AILIM.

8. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 1, wherein the substance is a non-protein substance.

9. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 8, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

10. (Currently Amended) A method of ~~pharmaceutical composition for~~ preventing~~,~~ or treating~~, or prophylaxis of~~ inflammation in a subject, the method comprising administering the subject an effective amount of a composition comprising (a) a substance that modulates ~~having an activity in modulating~~ signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier.

11. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 10, wherein the substance inhibits ~~has an activity in inhibiting~~ proliferation of AILIM-expressing cells or inhibits ~~in inhibiting~~ production of a cytokine by AILIM-expressing cells.

12. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 11, wherein the cytokine is interferon γ ~~which is a cytokine produced by Th1 type T cells,~~ or interleukin 4 ~~which is a cytokine produced by Th2 type T cells~~.

13. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 10, wherein the subject has ~~inflammation is~~ hepatitis.

14. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 10, wherein the substance is a protein ~~substance~~.

15. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 14, wherein the protein ~~substance~~ is selected from the group consisting of:

a) an antibody that ~~which~~ binds to AILIM or a portion thereof;

b) a polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM;

c) a fusion polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM and all ~~the whole~~ or a portion of a constant region of an immunoglobulin heavy chain; and

d) a polypeptide that ~~which~~ binds to AILIM.

16. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 10, wherein the substance is a non-protein substance.

17. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 16, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

18. (Currently Amended) A method of ~~pharmaceutical composition for~~ preventing~~,~~ or treating~~, or prophylaxis of~~ graft versus host reaction or ~~and~~ immune rejection accompanying graft versus host reaction or transplantation of a tissue or organ in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) a substance that modulates ~~having an activity in modulating~~ signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier.

19. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 18, wherein the substance inhibits ~~has an activity in inhibiting~~ proliferation of AILIM-expressing cells or inhibits ~~inhibiting~~ production of a cytokine by AILIM-expressing cells.

20. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 19, wherein the cytokine is interferon γ ~~which is a cytokine produced by Th1 type T cells,~~ or interleukin 4 ~~which is a cytokine produced by Th2 type T cells~~.

21. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 18, wherein the substance is a protein ~~substance~~.

22. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 21, wherein the protein ~~substance~~ is selected from the group consisting of:

a) an antibody that ~~which~~ binds to AILIM or a portion thereof;

b) a polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM;

c) a fusion polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM and all ~~the whole~~ or a portion of a constant region of an ~~in~~ immunoglobulin heavy chain; and

d) a polypeptide that ~~which~~ binds to AILIM.

23. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 18, wherein the substance is a non-protein substance.

24. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 23, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

25. (Currently Amended) A method of ~~pharmaceutical composition for~~ preventing or treating an immune response triggered by a foreign antigen or an autoantigen in a subject, the method comprising administering to the subject an effective amount of a composition comprising (a) a substance that modulates ~~having an activity of controlling~~ signal transduction mediated by AILIM, and (b) a pharmaceutically acceptable carrier.

26. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 25, wherein the immune response comprises ~~is~~ production of an antibody against the foreign antigen or the autoantigen, cell proliferation, or production of a cytokine.

27. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 25, wherein the substance inhibits ~~has an activity in inhibiting~~ proliferation of AILIM-expressing cells or inhibits ~~in inhibiting~~ production of a cytokine by AILIM-expressing cells.

28. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 27, wherein the cytokine is interferon γ ~~which is a cytokine produced by Th1 type T cells,~~ or interleukin 4 ~~which is a cytokine produced by Th2 type T cells~~.

29. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 25, wherein the substance is a protein ~~substance~~.

30. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 29, wherein the protein ~~substance~~ is selected from the group consisting of:

a) an antibody that ~~which~~ binds to AILIM or a portion thereof;

b) a polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM;

c) a fusion polypeptide comprising all ~~the whole~~ or a portion of an extracellular region of AILIM and all ~~the whole~~ or a portion of a constant region of an immunoglobulin heavy chain; and

d) a polypeptide that ~~which~~ binds to AILIM.

31. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 25, wherein the substance is a non-protein substance.

32. (Currently Amended) The method ~~pharmaceutical composition~~ of claim 31, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.